Anti-glomerular basement membrane disease in an HIV-infected patient (Q47569044)

4 February 2018

title

Anti-glomerular basement membrane disease in an HIV-infected patient (English)

1 reference

4 February 2018

3

Stanley C Jordan

1 reference

4 February 2018

Cynthia C. Nast

5

object named as

Cynthia C Nast

1 reference

4 February 2018

author name string

Eric Wechsler

1

1 reference

4 February 2018

Tom Yang

2

1 reference

4 February 2018

Ashley Vo

4

1 reference

4 February 2018

publication date

22 January 2008

1 reference

4 February 2018

Nature Clinical Practice Nephrology

published in

1 reference

4 February 2018

volume

4

1 reference

4 February 2018

issue

3

1 reference

4 February 2018

page(s)

167-171

1 reference

4 February 2018

Keynote Lecture: Starting r-HuEPO in chronic renal failure: when, why, and how?

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0724

Crescentic IgA nephropathy and acute renal failure in an HIV-positive patient with enteric salmonella infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0724

Anti-nuclear, anti-neutrophil cytoplasmic and anti-glomerular basement membrane antibodies in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0724

7 January 2021

The uncertain significance of anti-glomerular basement membrane antibody among HIV-infected persons with kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0724

7 January 2021

Anti-glomerular basement membrane glomerulonephritis in an HIV positive patient: case report

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0724

7 January 2021

AIDS and IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0724

7 January 2021

Crescentic IgA nephropathy as a manifestation of human immune deficiency virus infection

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0724

7 January 2021

Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0724

7 January 2021

Rituximab in idiopathic membranous nephropathy: a one-year prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0724

7 January 2021

Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0724

7 January 2021

Drug insight: rituximab in renal disease and transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0724

7 January 2021

Pulmonary renal syndrome due to anti-GBM and IgM C-ANCA disease requiring the use of novel therapeutic agents

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0724

7 January 2021

Goodpasture's syndrome treated with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0724

7 January 2021

ANCA-associated vasculitis: new options beyond steroids and cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0724

7 January 2021

Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0724

7 January 2021

Identifiers

DOI

10.1038/NCPNEPH0724

1 reference

4 February 2018

1 reference

4 February 2018